Search

Your search keyword '"Institut Curie-Hôpital"' showing total 192 results

Search Constraints

Start Over You searched for: Author "Institut Curie-Hôpital" Remove constraint Author: "Institut Curie-Hôpital"
192 results on '"Institut Curie-Hôpital"'

Search Results

1. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells

2. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting―IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms

3. germline mutations in women with familial breast cancer and a relative with haematological malignancy

4. BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer

5. Preparation of bactericidal cationic PDMS surfaces using a facile and efficient approach

6. Chromatin immunoprecipitation in microfluidic droplets: towards fast and cheap analyses

7. Droplet Microfluidic and Magnetic Particles Platform for Cancer Typing

8. Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

9. High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection

10. Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles

11. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

12. Preventing Biofilm Formation and Associated Occlusion by Biomimetic Glycocalyxlike Polymer in Central Venous Catheters

13. Preventing biofilm formation and associated occlusion by biomimetic glycocalyxlike polymer in central venous catheters

14. Biomimetic engineering of non-adhesive glycocalyx-like PDMS surfaces

15. Transducing properties of a pre-structured α-helical DPT-peptide containing a short canine adenovirus type 2 E4orf4 PP2A1-binding sequence

16. Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer

17. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1/2 carrier cohort (GENEPSO)

18. Facile and Efficient Control of Bioadhesion on Poly(dimethylsiloxane) by Using a Biomimetic Approach

19. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome

20. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

21. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

22. In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy

23. Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.

24. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.

25. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18 F-fluoroestradiol ( 18 F-FES) CT/PET.

26. [Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma].

27. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.

28. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.

29. Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

30. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

32. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

33. Diagnostic effectiveness of [ 18 F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study.

34. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.

35. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.

36. Geriatric impairments were directly and indirectly associated with mortality in older patients with cancer: a structural equation analysis.

37. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.

38. ESTABLISHMENT OF REGIONAL DIAGNOSTIC REFERENCE LEVELS IN ADULT COMPUTED TOMOGRAPHY FOR FOUR AFRICAN COUNTRIES: A PRELIMINARY SURVEY.

39. Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.

40. Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress.

41. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

42. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

43. Cancer in the older Indian population: Understanding the current context in an emerging economy.

44. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).

45. Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study.

46. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.

47. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.

48. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].

49. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].

50. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Catalog

Books, media, physical & digital resources